GP
NYMX

GLG Partners’s Nymox Pharmaceutical Corp NYMX Stock Holding History

GLG Partners’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-13,472
Closed -$49K – 461
2017
Q1 		$49K Buy
+13,472
New +$44.3K ﹤0.01% 437

Other funds holding NYMX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GLG Partners's NYMX Position: Q2 2017 in Review

GLG Partners sold out of Nymox Pharmaceutical Corp (NYMX) in Q2 2017, closing a stake of 13,472 shares — an estimated $49K sold.

GLG Partners first reported a position in NYMX in Q1 2017 and held it in 1 quarter. The position peaked at $49K in Q1 2017. 45 funds tracked by Wall St. Rank hold NYMX as of Q2 2017.

  • GLG Partners reported no remaining Nymox Pharmaceutical Corp position as of Q2 2017 after selling out during the quarter.
  • GLG Partners sold 13,472 Nymox Pharmaceutical Corp shares in Q2 2017, an estimated $49K.
  • GLG Partners first reported a position in Nymox Pharmaceutical Corp in Q1 2017 and held it in 1 quarter.
  • GLG Partners's Nymox Pharmaceutical Corp position peaked at $49K in Q1 2017.
  • 45 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q2 2017.

Based on GLG Partners's 13F filing for Q2 2017, filed 14 Aug 2017.